Last Updated : February 28, 2025
Details
Generic Name:
odevixibat
Project Status:
Received
Therapeutic Area:
Alagille syndrome
Manufacturer:
Medison Pharma Canada Inc.
Call for patient/clinician input open:
Brand Name:
Bylvay
Project Line:
Reimbursement Review
Project Number:
SR0884-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Odevixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Odevixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 20, 2025 |
|---|---|
| Call for patient/clinician input closed | March 18, 2025 |
| Submission received | February 28, 2025 |
| Submission accepted | - |
Last Updated : February 28, 2025